

VOLUMES 108–109 SUPPL. 1 MAY–JUNE 2022 ISSN 0969-8051

NUCLEAR MEDICINE AND BIOLOGY

FROM BENCH TO CLINICAL TRANSLATION
Molecular Targeting · Validation In Vitro & In Vivo · Radiotherapy

Abstracts of the
International Symposium on
Radiopharmaceutical Sciences
iSRS 2022

May 29 to June 2 2022
Nantes, France

The publication of this
abstract book was sponsored by the
Society of Radiopharmaceutical
Sciences

Official Journal of the Society of
Radiopharmaceutical Sciences

NUCLEAR MEDICINE AND BIOLOGY

EDITOR-IN-CHIEF

A. D. WINDHORST, VU University Medical Center, Amsterdam, The Netherlands, ad.windhorst@amsterdamumc.nl.

ASSOCIATE EDITOR

J. LEWIS, Memorial Sloan Kettering, Department of Radiology, New York, USA

Y. MAGATA, Hamamatsu University School of Medicine, Hamamatsu, Japan

EDITORS

A. J. AIRAKSINEN, Turku PET Centre, Turku, Finland

C. J. ANDERSON, University of Missouri, Missouri, USA

S. CHALON, INSERM and University of Tours, France

B. CORNELISSEN, Churchill Hospital, Oxford, UK

P. CUMMING, Inselspital, Universitätsspital Bern Universitätsklinik für Nuklearmedizin, Switzerland

C. CUTLER, Brookhaven National Laboratory, Upton, NY, USA

E. DADACHOVA, University of Saskatchewan, Saskatoon Saskatchewan, Canada

T. R. DEGRADO, University of Colorado, Aurora, CO, USA

W. DEUTHER-CONRAD, Helmholtz-Zentrum Dresden – Rossendorf, Leipzig, Germany

F. DOLLÉ, Service Hospitalier Frédéric Joliot, Orsay, France

A. DUATTI, University of Ferrara, Ferrara, Italy

H. M. HENNKENS, University of Missouri, Columbia, MO, USA

K. HERFERT, University Tuebingen, Germany

A. G. HORTI, Johns Hopkins University, Baltimore, MD, USA

G. D. HUTCHINS, Indiana University School of Medicine, Indianapolis, IN, USA

M. L. JAMES, Stanford University, Stanford, CA, USA

J. M. JEONG, Seoul National University College of Medicine, Seoul, Korea

H. JIA, Beijing Normal University, Beijing, China

S. S. JURISSON, University of Missouri, Columbia, MO, USA

H. F. KUNG, University of Pennsylvania, Philadelphia, PA, USA

S. LAPI, University of Alabama at Birmingham, USA

J. LINK, Oregon Health & Science University, Portland, OR, USA

Z. LIU, Houston Methodist Hospital, Houston, TX 77030, USA

R. MAIRS, Cancer Research UK Beatson Laboratories Glasgow, Scotland

D. A. MANKOFF, University of Pennsylvania Health System, Philadelphia, PA, USA

Y. MIAO, University of Colorado Denver, Aurora, CO, USA

T. L. MINDT, General Hospital Vienna (AKH), Vienna, Austria

E. MISHANI, Hadassah-Hebrew University, Jerusalem, Israel

G. PASCALI, Australian Nuclear Science and Technology Organisation, Camperdown NSW, Australia

B. E. ROGERS, Washington University School of Medicine, St. Louis, MO, USA

M. RUSCKOWSKI, University of Massachusetts Medical School, Worcester, MA, USA

S. W. SCHWARZ, Washington University School of Medicine, St. Louis, MO, USA

P. J. H. SCOTT, Michigan Medicine, Ann Arbor, MI, USA

N. SENECA, AbbVie Inc, North Chicago, IL USA

J. L. SUTCLIFFE, Department of Biomedical Engineering, UC Davis, Sacramento, USA

S. TERRY, Kings College London, London, UK

M. L. THAKUR, Thomas Jefferson University, Philadelphia, PA, USA

J. F. VALLIANT, McMaster University, Hamilton, Ontario, Canada

D. VERA, University of California San Diego Medical Center, San Diego, CA, USA

N. VIOLA, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

M. WUEST, Cross Cancer Institute, Edmonton, AB, USA

M. R. ZALUTSKY, Duke University Medical Center, Durham, NC, USA

X. ZHANG, Xiamen University, Xiamen, China

NUCLEAR MEDICINE AND BIOLOGY

FROM BENCH TO CLINICAL TRANSLATION
Molecular Targeting • Validation In Vitro & In Vivo • Radiotherapy

**Abstracts of the
International Symposium on
Radiopharmaceutical Sciences
iSRS 2022**

**May 29 to June 2, 2022
Nantes, France**

The publication of this abstract book was sponsored by
the Society of Radiopharmaceutical Sciences



AIMS AND SCOPE

Nuclear Medicine and Biology publishes original research addressing all aspects of **radiopharmaceutical science**: synthesis (automated and manual), *in vitro* and *ex vivo* studies, *in vivo* biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration.

These multidisciplinary studies should validate the mechanism of localization whether the tracer is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the tracer to changes in disease or treatment, although studies validating mechanism alone are acceptable as well.

If the synthesis of a new radiopharmaceutical is submitted without *in vitro* or *in vivo* data, then the uniqueness of the chemistry must be emphasized and should provide a substantial improvement over existing methodologies.

Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.

Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

Further Information on the Aims and Scope of Nuclear Medicine and Biology

Graphical abstract

A Graphical Abstracts is mandatory for this journal, please find more details here <https://www.elsevier.com/journals/nuclear-medicine-and-biology/0969-8051/guide-for-authors>

Introduction:

In keeping with the goal of translating the preclinical studies to the clinic, the introduction of your manuscript should contain the potential impact of the tracer on a particular disease.

Materials and Methods:

Given that validation of new targeted radiotracers is a primary goal of the journal, all new tracers should minimally have radiochemical yield (RCY), radiochemical purity (RCP), molar activity (MA), for reference see the publication 'Consensus nomenclature rules for radiopharmaceutical chemistry—Setting the record straight'. If not commercially available, for small molecules and peptides the precursor and cold reference should have identity (minimally ¹H-NMR, ¹³C-NMR, HRMS) and purity (minimally HPLC) reported, while for metal complexes and biologicals alternative analyses should be provided.

Identity of a new tracer is crucial information and should be assessed via minimally HPLC where the retention time is compared to a cold reference (eg ¹⁹F analog of the ¹⁸F tracer). In case a radionuclide does not have a stable isotope available, a surrogate element should be used instead (eg Re to use as surrogate of ^{99m}Tc).

In vivo evaluation of new tracer should minimally include assessment of the biodistribution and the metabolism of a new tracer, if not applicable this should be justified in the discussion of the manuscript.

All metrics should have an associated average value, standard deviation and number of studies. For small-animal images, the amount injected, the anesthesia used and the image duration should minimally be included in the figure caption so comparisons can be easily made. Correlation with tissue dissection data is recommended.

Manuscripts on pharmacy including those on automation that focus on the apparatus and the computer program should present substantially improved RCY, RCP, MA; shorter reaction time; or improved analytical techniques compared to the present state of the art. All new pharmacy approaches should be referenced as complying with standard applicable regulations. Radiation-absorbed dose (dosimetry) studies in humans should contain the full data set published as supplementary data. A comparison with small-animal dosimetry data is encouraged.

Publication Information: *Nuclear Medicine and Biology* (ISSN: 0969-8051) is published 12 times a year by Elsevier, 230 Park Avenue, Suite 800, New York, NY 10169. Months of issue are January, February, March, April, May, June, July, August, September, October, November, and December. Business Office: 1600 John F. Kennedy Blvd., Suite 1800, Philadelphia, PA 19103-2899. Accounting and Circulation Offices: 3251 Riverport Lane, Maryland Heights, MO 63043. Periodicals postage paid at New York, NY, and at additional mailing offices.

Orders, claims, and journal inquiries: Please visit our Support Hub page <https://service.elsevier.com> for assistance.

For advertising inquiries for North and South America, please contact Marjorie Valle, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169; e-mail: c.melis@elsevier.com. For international advertising information, contact the Advertising Department, Elsevier Inc., The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; telephone: 44-0-1865-843565; fax: 44-0-1865-843976; e-mail: media@elsevier.co.uk. For advertising in Japan, contact the Advertising Department, Elsevier Inc. K.K.; telephone: 81-3-5561-5033; fax: 81-3-5561-5047.

Reprints: For copies of 100 or more, of articles in this publication, please contact the Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169; Tel. (212) 633-3813; fax: (212) 633-3820; e-mail: reprints@elsevier.com

USA POSTMASTER: Send address changes to *Nuclear Medicine and Biology*, Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA.

Subscription Rates (2022): Personal price: US\$ 622 for the United States, US\$ 711 for Rest of World. Prices include postage and are subject to change without notice.

© 2022 Elsevier Inc. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright, and the following terms and conditions apply to their use in addition to the terms of any Creative Commons or other user license that has been applied by the publisher to an individual article:

Photocopying. Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Derivative Works. Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company.

For any subscribed articles or articles published under a CC BY-NC-ND license, permission of the publisher is required for all other derivative works, including compilations and translations.

Storage or Usage. Except as outlined above or as set out in the relevant user license, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Permissions. For information on how to seek permission visit www.elsevier.com/permissions.

Author rights. Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at <http://www.elsevier.com/authorsrights>).

Notice. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

*Author submission guidelines can be found at:
<http://www.nucmedbio.com/authorinfo>.



May 29 to June 2, 2022

INTERNATIONAL SCIENTIFIC PROGRAM COMMITTEE

Guy Bormans, PhD, KU Leuven, Belgium
Cathy S. Cutler, PhD, Brookhaven National Laboratory, USA
Antony Gee, PhD, King's College London, UK
Sandrine Huclier, PhD, Subatech and Arronax, France (Chair)
Yuji Kuge, PhD, Hokkaido University, Japan
Bertrand Kuhnast, PhD, Service Hospitalier Frédéric Joliot, CEA, France
Nicolas Lepareur, PhD, Centre Eugene Marquis, France
Jason Lewis, PhD, Memorial Sloan Kettering Cancer Center, USA
Cécile Perrio, PhD, Cyceron, France
Henry VanBrocklin, PhD, University of California San Francisco, USA
Johnny Vercouillie, PhD, University of Tours, France
Daniëlle Vugts, PhD, Amsterdam UMC, VU University, The Netherlands

LOCAL ORGANIZING COMMITTEE

Mickaël Bourgeois, Nantes Université
Nicolas Galland, Nantes Université
Marie-Hélène Gaugler, Nantes Université
Jean-François Gestin, Inserm
Céline Hérault, GIP ARRONAX
Sandrine Huclier, Nantes Université
Bertrand Kuhnast, CEA
Françoise Léost, Cancéropôle Grand Ouest
Nicolas Lepareur, Comprehensive Cancer Center Eugène Marquis-Rennes
Anne Le Pennec, Nantes Université
Cécile Perrio, CNRS
Johnny Vercouillie, Université de Tours
Valérie Viranaiken, Nantes Université

ABSTRACT REVIEWERS

Anu Airaksinen	Pavithra H. A. Kankanamalage	Zhibo Liu	Valery Radchenko
Roger Alberto	Christer Halldin	Jordi Llop Roig	Caterina Ramogida
Simon Ametamey	Mohammad Haskali	Reik Loeser	Yi Rao
Carolyn Anderson	Heather Hennkens	Robert Mach	David Reichert
Gunnar Antoni	Matthias Herth	Theodosia Maina-Nock	Sheryl Roberts
Alejandro Arroyo	Cornelia Hoehr	Constantin Mamat	Tobias Ross
Mattia Asti	Alexander Hoepping	Markus Mitterhauser	Benjamin Rotstein
Miguel Avila-Rodriguez	Stephan Holger	Angel Moldes-Anaya	Samuel Samnick
David Bauer	Sandrine Huclier	Linjing Mu	Mirkka Sarparanta
Neydher Berroteran-Infante	Bieneke Janssen	Takahiro Mukai	Paul Schaffer
Rajiv Bhalla	Andreas Jensen	Jogeshwar Mukherjee	Roger Schibli
Aleksander Bilewicz	Svend Jensen	Kjell Nagren	Peter Scott
Hendrikus Boersma	Jae Min Jeong	Bernd Neumaier	Alberto Signore
Cristina Bolzati	Hongmei Jia	Dana Niculae	Sarah Spreckelmeyer
Mickaël Bourgeois	Silvia Jurisson	Kazuma Ogawa	Jeff Stehouwer
Martin Brechbiel	Michael Kassiou	Mikako Ogawa	Jorg Steinbach
Peter Brust	Dong Wook Kim	Chris Orvig	Jun Toyohara
Dae Yoon Chi	Anna Kirjavainen	Alan Packard	R. Michael van Dam
Yearn Seong Choe	Yasushi Kiyono	Mukesh Pandey	Henry VanBrocklin
Joong-Hyun Chun	Torsten Kniess	Dionysia Papagiannopoulou	Johnny Vercouillie
John Clark	Klaus Kopka	Claudio Pascali	Chrysoula Vraka
Heinz Coenen	Raisa Krasikova	Giancarlo Pascali	Danielle Vugts
Mengchao Cui	Manja Kubeil	Cecile Perrio	Bjoern Waengler
Cathy S. Cutler	Yuji Kuge	Michael Phipps	Fan Wang
Clemens Decristoforo	Bertrand Kuhnast	Verena Pichler	Mingwei Wang
Frederic Dolle	Hank Kung	Markus Piel	Kohshin Washiyama
Paul Donnelly	Peter Larsen	Hans-Jurgen Pietzsch	Albert Windhorst
William Eckelman	Markus Laube	Jens Pietzsch	Frank Wuest
Philip Elsinga	Kyo Chul Lee	Victor Pike	Yangchun Xin
Shozo Furumoto	Yun-Sang Lee	Naga Vara Kishore Pillarsetty	Min Yang
Katie Gagnon	Jason Lewis	Federica Pisaneschi	Xing Yang
Antony Gee	Michael Lewis	Alex Poot	Jeongsoo Yoo
Nic Gillings	Xiang-Guo Li	Edwin Pratt	Alexander Yordanov
Matthew Gott	Yawen Li	Syed Qaim	Ming-Rong Zhang
Francois Guérard	Steven Liang	Thomas Quinn	Xianzhong Zhang

Introduction to this Abstract Supplement

We are delighted to finally hold the 24th International Symposium on Radiopharmaceutical Sciences in-person in Nantes, France, May 29 to June 2, 2022.

The meeting will take place in the form of invited keynote presentations, 15-minute oral abstract presentations (including three minutes for Q&A), 3-minute thesis presentations, poster presentations, and 1–2 min videos submitted as part of a Radiopharmaceutical Sciences Olympiad competition. Of course, there will be plenty of opportunities for informal interaction, including an opening party in the exhibit hall, various breaks, and an afternoon excursion.

Since some presenters could not know of their ability to attend before abstracts needed to be submitted to the publisher, leadership decided to publish all confirmed oral presenter abstracts and all abstracts accepted for poster presentation. Undoubtedly, some abstracts in the supplement will not be available for poster viewing (due to institutional, COVID-related restrictions), but we still thought that there was benefit to publishing all the poster abstracts.

Sandrine Huclier, PhD

Subatech and Arronax
Nantes, France
iSRS 2022 Program Chair

CONTENTS

Introduction to this Abstract Supplement	vi
Abstracts	S1
Keynote Summaries	S1
Oral Presentations	S4
Scientific Session 1: Neurology (Session A)	S4
Scientific Session 2: Radiometals	S6
Scientific Session 3: Theranostics	S10
Scientific Session 4: Nanomedicine	S13
Scientific Session 5: ¹⁸ F - Session A	S15
Scientific Session 6: Oncology (Imaging - Session A)	S17
Scientific Session 7: Targetry	S20
Scientific Session 8: Automation	S22
Scientific Session 9: Neurology (Session B)	S24
Scientific Session 10: ¹¹ C	S27
Scientific Session 11: Oncology (Therapy)	S30
Scientific Session 12: Bioconjugation	S34
Scientific Session 13: ¹⁸ F - Session B	S35
Scientific Session 14: Oncology (Imaging - Session B)	S37
Scientific Session 15: Multimodality	S41
Scientific Session 16: Miscellaneous	S42
Scientific Session 17: Other Fields	S44
Scientific Session 18: 3-Minute Thesis	S45
Scientific Session 19: NMB - Elsevier Award	S49
Poster Presentations	S52
Theranostics	S52
Applications of radiolabeled compounds in other fields	S62
¹¹ C - Radiochemistry	S70
¹⁸ F - Radiochemistry	S75
Applications of radiolabeled compounds in neurosciences	S89
New biological vectors in radiopharmaceutical sciences and bioconjugation strategies	S114
Automation / Microfluidics / Process Development	S121
Radiopharmacy	S140
Radiometals - Chemistry	S147
Nanomedicine	S160
Multimodality Imaging Probes	S166
Targetry	S169
Miscellaneous	S172
Applications of radiolabeled compounds in oncology	S180
Author Index	S223

affinity in mouse and human plasma was studied using an ultrafiltration assay. Biodistribution and SPECT/CT imaging studies were performed in FR-positive KB tumor-bearing nude mice.

Results: FR-binding affinity of the folate radioconjugates was in the nanomolar range (1.7–4.7 nM) with a trend of higher affinity for the 6S-5-MTHF-based radioconjugates. This was in line with the higher cell uptake (48–56%) of the 6S-5-MTHF-based radioconjugates as compared to 6R-5-MTHF-based (30–45%) and folic acid-based radioconjugates (25–43%). The albumin-binding affinity was enhanced for AMBA-containing radioconjugates. Folate radioconjugates modified with 4-(*p*-iodophenyl)butanoate (Groups 1 and 3) showed an up to 11-fold increased albumin-binding affinity than those equipped with 4-(*p*-iodophenyl)pentanoate (Groups 24 and 25). Consequently, radioconjugates of Groups 1 and 3 showed higher retention of activity in the blood pool (up to 8.7% IA/g; 24 h p.i.) than those with the weak albumin binder (Groups 24 and 25: <0.2% IA/g; 24 h p.i.). Importantly, the 5-MTHF-based radioconjugates exhibited enhanced blood retention (up to 8.7% IA/g; 24 h p.i.) compared to the folic acid-based counterparts (<1% IA/g; 24 h p.i.). On the other hand, kidney retention was lower for folate radioconjugates with the strong albumin binder (Groups 1 and 3: 12–70% IA/g; 24 h p.i.) than for those with the weak albumin binder (Groups 24 and 25: 33–143% IA/g; 24 h p.i.). Within the same group, kidney uptake was 1.7- to 2.9-fold increased for the 6S-5-MTHF radioconjugates compared to the other two candidates. Tumor uptake was more favorable for 5-MTHF radioconjugates than for folic acid radioconjugates (26–47% IA/g vs. 14–20% IA/g; 24 h p.i.), whereas the incorporated albumin binder had only a minor impact (Figure 1B) [3]. SPECT/CT studies with tumor-bearing mice confirmed these findings.

Conclusion: The selection of each functional unit and their interplay had a decisive impact on the distribution pattern of these novel folate radioconjugates. It remains to be demonstrated clinically,

which features are most relevant to enable a safe and effective application of folate radioconjugates for therapeutic purposes.

References:

- [1] Dumelin et al., *Angew. Chem. Int. Ed. Engl.* 2008;47:3196–3201
- [2] Deberle et al., *Bioconjug Chem* 2021;32:1617–1628
- [3] Guzik et al., *EJNMMI* 2020;48:972–983

O-14

Design and synthesis of a new bifunctional chelating agent for $^{18}\text{F}\text{-Al}/^{177}\text{Lu}$ radiolabelling: theranostic approach

Lauren Wagner¹, Raül Losantos¹, Céline Frochet¹, Gilles Karcher², Antonio Monari³, Charlotte Collet¹, Samir Acherar¹
¹Université de Lorraine, France, ²Nancyclotep, Plateforme d'imagerie moléculaire, France, ³Université de Paris, France

Objectives: Theranostic and personalized medicine are blooming as strategies to improve patients health care and provide early treatment [1]. Access to ^{18}F -radiochemistry for theranostic application is attractive due to imaging property of fluorine-18. However, to perform diagnosis by PET with fluorine-18 and β^- therapy with lutetium-177, the use of two different chelating agents (NOTA and DOTA respectively) was required [2]. To overcome this issue, we propose herein to develop a new general chelating agent named NO2A-AHM, labelled with different types of emitters (β^+ , β^- and γ) using the mismatched pair ($^{18}\text{F}\text{-Al}/^{177}\text{Lu}$). Moreover, this agent can be coupled to targeting units containing a thiol function such as peptides. Experimental and computational chemistry was performed to confirm the capacity of our chelating agent to label aluminum-fluorine and lutetium.

Methods: Different strategies to synthesize the original chelating agent NO2A-AHM were realized. Complexation ability of the new chelator was also evaluated using molecular modeling approaches at DFT level of theory. Experimental complexation study was also performed with aluminum-fluorine-19 and lutetium-175. Thiol-maleimide click chemistry was used to couple NO2A-AHM to the targeting agents Cys-Trp-DUPA and c(RGDfC).

Results: This new bifunctional chelating agent for theranostic applications is based on a hydrazine moiety functionalized by a NOTA cycle, a chelating arm, and a linker with a maleimide function. This design was chosen to allow the formation of 5 to 7 coordination bonds with a metal. The complexation of aluminum-fluorine, gallium and lutetium has been confirmed by molecular modeling justifying our chosen approach. NO2A-AHM was synthesized in 6 steps with an overall yield of 10%. Coupling of the bifunctional chelating agent with cysteine containing targeting agent was realized thanks to thiol-maleimide click reaction leading to the two precursors NO2A-AHM-Cys-Trp-DUPA and NO2A-AHM-c(RGDfC) with a yield of 77% and 77% respectively. Complexation was realized with non-radioactive cation metals (aluminum-fluorine-19 and lutetium-175) on NO2A-AHM and on peptide-precursor compounds (NO2A-AHM-Cys-Trp-DUPA, NO2A-AHM-c(RGDfC)) with yields of 70–80%.





Figure 1: (A) Chemical structures of the novel folate conjugates. (B) Tumor-to-kidney ratios determined based on biodistribution data obtained at 1 h, 4 h and 24 h after injection of respective radioconjugates.

Conclusions: The proof of concept of the ability of NO2A-AHM to complex aluminum-fluorine for further PET imaging applications and lutetium for therapeutic applications has been successfully achieved and is encouraging for the development of the theranostic approach. Further investigations will be performed using gallium to obtain ^{68}Ga -radiotracer for PET imaging applications. Radiolabelling of this new chelating agent with aluminum-fluorine-18 and lutetium-177 is under investigation.

Acknowledgments: We thank the Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation and Nancyclotep for PhD funding.

References:

- [1] Yordanova et al. *Theranostics in Nuclear Medicine Practice*. *OncoTargets Ther.* 2017, 10, 4821–4828, doi:10.2147/OTT.S140671.
- [2] Notni et al. Thinking the Role of Radiometal Isotopes: Towards a Future Concept for Theranostic Radiopharmaceuticals. *J. Label. Compd. Radiopharm.* 2018, 61, 141–153, doi:10.1002/jlcr.3582.
- [3] McBride et al. Radiofluorination Using Aluminum-Fluoride (Al^{18}F). *EJNMMI Res.* 2013, 3, 36, doi:10.1186/2191-219X-3-36.

O-15


At-211-labeled L-tyrosine derivatives via neopentyl scaffold for targeted α -therapy

Yuta Kaizuka¹, Hiroyuki Suzuki¹, Tadashi Watabe², Yoshifumi Shirakami², Kazuhiro Ooe², Takahiro Teramoto³, Atsushi Toyoshima², Tomoya Uehara¹

¹Chiba University, Japan, ²Osaka University, Japan, ³IRS, Osaka University

Objectives: L-Type amino acid transporter 1 (LAT1) is up-regulated in various tumors. Therefore, radiolabeled amino acid derivatives transported by LAT1 have been developed for tumor diagnosis and used in clinical stages. Astatine-211 (^{211}At) is an α -emitter and belongs to halogen as same as fluorine-18 (^{18}F) and radioiodine. So, ^{211}At -labeled amino acid derivatives have been developed as radiotherapeutic agents. However, deastatination from ^{211}At -labeled amino acid derivatives has been observed, and its improvement is desired. Recently, we reported neopentyl glycol as a platform to prepare ^{211}At -labeled compounds with high *in vivo* stability against deastatination [1]. In this study, to develop a ^{211}At -labeled amino acid derivative, we designed, synthesized, and evaluated neopentyl glycol conjugated amino acids as a candidate for targeted α -therapy.

Methods: Since the substituent modifications of the hydroxy group in the tyrosine side chain would be tolerant for the recognition by LAT1, a neopentyl scaffold was introduced into the hydroxy group to prepare NpTyr (Figure). Before evaluating [^{211}At]At-NpTyr, [^{125}I]I-NpTyr was also prepared and evaluated the amino acid transport mechanism using C6 cell line and the biodistribution in C6 tumor-bearing mice because ^{211}At -Np derivatives showed similar properties



X= ^{125}I : [^{125}I]I-NpTyr
 ^{211}At : [^{211}At]At-NpTyr

Figure. Structure of the evaluated agents

to [^{125}I]I-Np derivatives. Finally, the biodistribution of [^{211}At]At-NpTyr in normal mice was compared with [^{125}I]I-NpTyr.

Results: [^{125}I]I-NpTyr and [^{211}At]At-NpTyr were obtained in 47% and 48% radiochemical yields, respectively, and over 98% radiochemical purities after HPLC purification. [^{125}I]I-NpTyr was incorporated into the cells in a time-dependent manner. In the presence of 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH), an inhibitor of system L transporter or alpha-methyl-L-tyrosine (AMT), LAT1 substrate, the uptake of [^{125}I]I-NpTyr was reduced to 15% and 19%, respectively. Tumor accumulation of [^{125}I]I-NpTyr in C6 tumor-bearing mice was comparable to that of 3-[[^{125}I]iodo- α -methyl-L-tyrosine ([^{125}I]IMT). Both [^{125}I]I-NpTyr and [^{211}At]At-NpTyr exhibited low accumulation in the stomach and the neck and similar biodistribution profiles in normal mice.

Conclusions: [^{125}I]I-NpTyr was transported into C6 cells with the involvement of LAT1, and the tumor accumulation of [^{125}I]I-NpTyr *in vivo* was comparable to the conventional amino acid tracer. [^{125}I]I-NpTyr and [^{211}At]At-NpTyr exhibited similar pharmacokinetics in normal mice. These findings suggest that [^{211}At]At-NpTyr is a good candidate for targeted α -therapy.

Acknowledgment: This work was supported in part by a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science, grant number 19K08222. ^{211}At was supplied through the Supply Platform of Short-lived Radioisotopes, supported by JSPS Grant-in-Aid for Scientific Research on Innovative Areas, grant number 16H06278.

References:

- [1] H. Suzuki, Y. Kaizuka, et al., *J. Med. Chem.* 2021, 64, 15846-15857

Scientific Session 4: Nanomedicine

O-16

Tetrazine ligation based pretargeting strategy for core-labeled polymeric micelles

Emanuel Sporer¹, Christian Poulie², Jesper Jørgensen², Andreas Kjær², Matthias Herth², Andreas Tue Ingemann Jensen³

¹Technical University of Denmark, Denmark, ²University of Copenhagen, Denmark, ³LiPlasome Pharma A/S, Denmark

Objectives: Polymeric micelles (PMs) can be used to deliver therapeutic substances and radionuclides to tumor lesions. The most common targeting strategy is passive accumulation via the enhanced permeability and retention effect (EPR). However, the EPR effect only results in limited and slow accumulation, and cannot target micrometastases. For these reasons, EPR is not compatible with targeted radionuclide therapy. Here we present a new strategy for active targeting of PMs via biorthogonal pretargeting. PMs consisting of polyethylene glycol (PEG) and poly(lactic-co-glycolic acid) (PLGA) co-polymers were surface modified with tetrazines (Tz). These Tz-PMs can be injected three days after a transcyclooctene (TCO) modified antibody has been administered and accumulated in the tumor (Figure 1). The PMs then accumulate in the tumor via the Tz-TCO ligation.

Methods: *Synthesis:* NH_2 -PEG(5k)-PLGA(10k) was modified with either 2,5-dioxopyrrolidin-1-yl 2-(4-(1,2,4,5-tetrazin-3-yl)phenyl)acetate or DOTA, via their NHS derivatives. PEG(5k)-PLGA(10k)- NH_2 was modified with 2,5-dioxopyrrolidin-1-yl 3-(trimethylstannyl)benzoate (Figure 2). After synthesis, the resulting functionalized polymers were mixed in DMF in different ratios, along with unmodified PEG(5k)-PLGA(10k). Slow addition of water caused formation of PMs, which were purified by sequential concentration on centrifuge filters. To monitor PMs *in vivo*, we co-labeled them with copper-64, as well as with iodine-125 via a recently developed covalent core-labeling strategy that is also applicable to astatine-211.